Literature DB >> 15647927

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.

Paul F Schellhammer1, Robert M Hershberg.   

Abstract

Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15647927     DOI： 10.1007/s00345-004-0475-z

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  7 in total

Review 1.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

2.  Identification of T helper epitopes from prostatic acid phosphatase.

Authors:  D G McNeel; L D Nguyen; M L Disis
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

Authors:  J Schmielau; O J Finn
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

4.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Authors:  Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer.

Authors:  Huiming Zhang; Jonathan Melamed; Ping Wei; Karen Cox; Wendy Frankel; Robert R Bahnson; Nikki Robinson; Ron Pyka; Yang Liu; Pan Zheng
Journal:  Cancer Immun       Date:  2003-02-14

6.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

7.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.

Authors:  Yiping Yang; Ching-Tai Huang; Xiaopei Huang; Drew M Pardoll
Journal:  Nat Immunol       Date:  2004-04-04       Impact factor: 25.606
  7 in total
  2 in total

1.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Authors:  Yi T Koh; Andrew Gray; Sean A Higgins; Bolyn Hubby; W Martin Kast
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

2.  Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.

Authors:  Martha Q Lacy; Sumithra Mandrekar; Angela Dispenzieri; Suzanne Hayman; Shaji Kumar; Francis Buadi; David Dingli; Mark Litzow; Peter Wettstein; Douglas Padley; Brian Kabat; Dennis Gastineau; S Vincent Rajkumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2009-12       Impact factor: 10.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.